News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CereSpir Incorporated is Pleased With Positive Interim Phase 2 Results for CHF 5074 in Patients With Mild Cognitive Impairment, Presented by Chiesi Farmaceutici SpA at the AAIC 2013 Meeting in Boston


7/26/2013 9:53:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, July 26, 2013 (GLOBE NEWSWIRE) -- CereSpirâ„¢ Incorporated announced positive interim clinical results from Chiesi Farmaceutici's Phase 2 study testing CHF 5074, a novel, first-in-class small molecule microglia modulator, in patients with mild cognitive impairment (MCI). The 90-week study, which included a 96-patient 14-week double-blind, placebo-controlled study and an ongoing 76-week open-label extension study, tested three titrated doses of CHF 5074 (200 mg, 400 mg, 600 mg dosed orally once daily) in MCI patients. Upon completion of the 14-week study,

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES